Reaching a milestone in diabetes care in Sri Lanka, Gamma Interpharm (Pvt) Ltd. launched Glyclapan MR 60mg, a Gliclazide Modified Release 60mg tablet, in Colombo last week.
Medical professionals, stakeholders, and guests were present.
Glyclapan MR 60 is the first clinically proven Gliclazide Modified-Release 60mg tablet to be manufactured in Sri Lanka. The Bioequivalence (BE) study was conducted at Kotelawala Defence University (KDU), confirming its therapeutic equivalence to the innovator brand, a company official said. What makes this achievement even more significant was that the study was carried out in Sri Lanka to ensure that Glyclapan MR 60 is well-suited for the physiological profiles and healthcare needs of the local population.
The guest speaker, Consultant Paediatric Endocrinologist at Birmingham Women’s and Children’s Hospital (BWC), Dr. Suma Uday spoke on the emerging societal issue of childhood obesity and type 2 diabetes.
Consultant Interventional Cardiologist and Principal Investigator for the BE studies at KDU, Prof. Pandula Athauda-Arachchi outlined the significance of bioequivalence (BE) studies and provided valuable insights into how these studies are conducted at KDU aligned to the theme of the event.
The company’s state-of-the-art manufacturing facility in Madapatha, Piliyandala complies with the guidelines for Good Manufacturing Practices (GMP) adopted by the National Medicines Regulatory Authority (NMRA) of Sri Lanka, from the World Health Organization (WHO) GMP main principles for pharmaceutical products.
Gamma Interpharm (Pvt) Ltd has expanded into Myanmar, the Maldives, Cambodia, Vietnam, and the Philippines, meeting international standards.
